| 1.0E-6 -0 (-99%) | 11-22 10:15 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0 | 1-year : | 0 |
| Resists | First : | 0 | Second : | 0 |
| Pivot price | 0 |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0 |
MA(20) : | 0 |
| MA(100) : | 0 |
MA(250) : | 0.01 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 51.4 |
D(3) : | 44.8 |
| RSI | RSI(14): 34.9 |
|||
| 52-week | High : | 0.13 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ KLDO ] has closed below the lower bollinger band by 7.7%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ KLDO ] is to continue within current trading range. It is unclear right now based on current values. 93.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 46 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0 - 0 | 0 - 0 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0 | 0 - 0 |
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Mon, 06 Nov 2023
Head to Head Review: Organovo (NASDAQ:ONVO) & Kaleido Biosciences (NASDAQ:KLDO) - Defense World
Fri, 08 Apr 2022
Kaleido Biosciences shuts down - Boston Business Journal - The Business Journals
Fri, 08 Apr 2022
KLDO stock crashes on plans to delist from Nasdaq (NASDAQ:KLDO) - Seeking Alpha
Mon, 06 Dec 2021
Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome ... - GlobeNewswire
Thu, 09 Jan 2020
Kaleido Biosciences Announces Collaboration with Janssen to Explore the Potential for Microbiome Metabolic ... - GlobeNewswire
Mon, 02 Dec 2019
Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
PNK
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 4.245e+007 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 2,160 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.516e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 927.7 % |
| Return on Equity (ttm) | -100 % |
| Qtrly Rev. Growth | 1.1e+006 % |
| Gross Profit (p.s.) | 209.18 |
| Sales Per Share | -1184.84 |
| EBITDA (p.s.) | -1.36122e+008 |
| Qtrly Earnings Growth | -2.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -77 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 2.34e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|